Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) CFO Sells $10,661.40 in Stock

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE – Get Rating) CFO James E. Fickenscher sold 17,769 shares of the business’s stock in a transaction on Monday, January 23rd. The shares were sold at an average price of $0.60, for a total transaction of $10,661.40. Following the transaction, the chief financial officer now owns 154,736 shares of the company’s stock, valued at $92,841.60. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Zynerba Pharmaceuticals Price Performance

Zynerba Pharmaceuticals stock traded down $0.03 during mid-day trading on Wednesday, hitting $0.60. The company’s stock had a trading volume of 128,532 shares, compared to its average volume of 264,483. The stock has a market cap of $27.45 million, a price-to-earnings ratio of -0.69 and a beta of 1.64. The business has a 50 day moving average price of $0.57 and a 200-day moving average price of $0.84. Zynerba Pharmaceuticals, Inc. has a 12 month low of $0.49 and a 12 month high of $2.94.

Zynerba Pharmaceuticals (NASDAQ:ZYNE – Get Rating) last posted its quarterly earnings results on Monday, November 14th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.01. On average, equities research analysts expect that Zynerba Pharmaceuticals, Inc. will post -0.86 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ZYNE. HC Wainwright lowered shares of Zynerba Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Tuesday, November 1st. StockNews.com raised shares of Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 19th.

Institutional Trading of Zynerba Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in ZYNE. Cetera Advisor Networks LLC bought a new stake in Zynerba Pharmaceuticals in the second quarter worth $28,000. Verition Fund Management LLC bought a new position in shares of Zynerba Pharmaceuticals during the second quarter valued at about $35,000. Jane Street Group LLC bought a new position in shares of Zynerba Pharmaceuticals during the third quarter valued at about $46,000. UBS Group AG raised its stake in shares of Zynerba Pharmaceuticals by 145.2% during the first quarter. UBS Group AG now owns 27,621 shares of the company’s stock valued at $56,000 after acquiring an additional 16,357 shares during the last quarter. Finally, Two Sigma Investments LP bought a new position in shares of Zynerba Pharmaceuticals during the third quarter valued at about $90,000. 23.82% of the stock is owned by institutional investors.

About Zynerba Pharmaceuticals

(Get Rating)

Zynerba Pharmaceuticals, Inc engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on the research and development of rare and near-rare neuropsychiatric conditions. The firm offers the Zygel product, which is formulated as a permeation-enhanced gel for transdermal delivery.